TY -的T1 Non-thymomatous重症肌无力胸腺切除术:结果从MGTX,随机,对照试验(S28.003) JF -神经学乔-神经学六世- 86 - 16补充SP - S28.003 AU -加里刀盟-亨利·卡明斯基非盟-吉尔·沃尔夫盟Immacu首页lada波斯历八月盟——代表MGTX试验研究小组Y1 - 2016/04/05 UR - //www.ez-admanager.com/content/86/16_Supplement/S28.003.abstract N2 -目的:是否延长transsternal胸腺切除术(ETTX)结合强的松协议定义,较强的松协议单独:导致了更大的改善肌无力的弱点;结果在一个较低的总剂量的强的松;和提高生活质量,减少不良事件?背景自1941年首次使用,受益于non-thymomatous重症肌无力胸腺切除术(MG)已被大量研究声称。2000年,一个以证据为基础的回顾总结结果来自21个控制,非随机性毫克军团,指出方法论的缺陷预防有关程序的效益和得出结论,明确的结论胸腺切除术治疗选择。与电话追溯到半个世纪,评论者建议控制随机研究,采用标准化的药物治疗。方法MGTX五洲,组织国际、单盲、随机试验,目的是要回答三个问题提出以上。入选标准是MG基金会美国临床分类2到4,乙酰胆碱受体抗体水平升高,年龄在18.0 & lt; 65.0岁,和疾病历史& lt; 5年。患者随访以单盲方式至少3年。结果共有126名患者参加2006年和2012年之间在36个站点。 The mean age was 35.1 years. MGFA Class at the time of randomization: 39.7[percnt] were class IIa, 25[percnt] Class IIb , 22[percnt] Class IIIa, 10.3[percnt] Class IIIb, and 2[percnt] Class IVa and Class IVb combined. Sixty percent were diagnosed within a year of onset. CONCLUSIONS A result favoring thymectomy would establish its benefits unequivocally; failure to show a difference would suggest that thymectomy is an unnecessary procedure in this non-thymomatous population and should lead to cost savings. Thus the results will impact on clinical practice. The last patient out will occur in November 2015 and final results of the practice changing trial will be presented.Disclosure: Dr. Cutter has received personal compensation for activities with Apotek, Ascendis Pharma, Biogen Idec, Cleveland Clinic, and GlaxoSmithKline. Dr. Kaminski has received personal compensation for activities with Novartis and ARC Biotechnology as a DSMB member and as a member of the Chief Medical Advisory Board. Dr. Wolfe has received personal compensation for activities with Grifols and Baxter as a speakers bureau participant and/or advisory board participant. Dr. Aban has nothing to disclose. Dr. MGTX Trial Research Group has nothing to disclose.Tuesday, April 19 2016, 6:30 am-8:30 am ER -